Medicare GLP-1 Bridge to Cover Wegovy Starting July 1
Medicare's Bridge program will cover Wegovy, Zepbound KwikPen, and Foundayo at a flat $50 copay starting July 1, 2026 for eligible Part D enrollees.
May 7, 2026 · 2 min read
The Centers for Medicare & Medicaid Services confirmed Wegovy will be among the GLP-1s covered under the new Medicare GLP-1 Bridge, a temporary program launching July 1, 2026 that gives eligible Part D beneficiaries a flat $50 monthly copay for weight-loss medications previously excluded from Medicare entirely.
What happened
The Bridge — a precursor to the longer-term BALANCE model — runs from July 1, 2026 through December 31, 2027. Covered products at launch include the injectable and oral forms of Wegovy, the KwikPen formulation of Zepbound, and Novo's Foundayo pill. Coverage applies through Medicare Part D plans only; beneficiaries must already be enrolled.
Eligibility hinges on body weight and comorbidity. Patients with a BMI of 35 or higher automatically qualify. Patients with a BMI of 27 or higher qualify if they also have a qualifying condition such as cardiovascular disease or prediabetes.
The flat $50 copay is fixed across dose strengths — it does not increase as patients titrate up. Two important caveats: the copay does not count toward the Part D deductible, and it does not count toward the $2,100 annual out-of-pocket cap on prescription drug costs.
Why it matters
Medicare has covered GLP-1s for diabetes for years, but obesity-only prescriptions have been categorically excluded under a 2003 statute that bars coverage of weight-loss drugs. The Bridge sidesteps that by operating as a CMS Innovation Center demonstration rather than a permanent benefit, which is also why the program has an expiration date and a finite formulary.
For patients, this is the first time injectable Wegovy and oral Foundayo will be available to Medicare enrollees solely on the basis of obesity. Before the Bridge, the only path to coverage was an off-label diabetes diagnosis or paying cash — typically over $1,000 per month at retail.
KFF analysts have flagged that the program is likely to add billions in new Medicare drug spending annually, depending on uptake. That cost question is what makes the post-2027 future uncertain.
What to watch
Three things will shape how widely the Bridge actually gets used. First, plan participation: not every Part D plan is required to participate, and beneficiaries may need to switch plans during fall open enrollment. Second, prior-authorization friction — early CMS guidance suggests plans can require BMI documentation and step therapy. Third, whether Congress acts to make obesity coverage permanent before the demonstration sunsets at the end of 2027.
For background on how Wegovy compares to Ozempic at the same molecule and dose, see Ozempic vs. Wegovy.
Sources
Sources